Journal Watch · Nature Medicine · 2026

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

Petersen KK, Milà-Alomà M, Li Y et al.Nature Medicine3 min readPharma relevance 65/100

DOI: 10.1038/s41591-026-04206-yPMID: 41714746Study type: cohort / observational clinical study

TL;DR

These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

Key findings

  • Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals.
  • Similar models were constructed with data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays.
  • These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

Numbers at a glance (from the abstract)

n = 258n = 345

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R<sup>2</sup> of 0.337-0.612) with a median absolute error of 3.0-3.7 years.

Full abstract (original)

Background: Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer's disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible.

What they did: Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R<sup>2</sup> of 0.337-0.612) with a median absolute error of 3.0-3.7 years.

Results & conclusions: Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

Abstract © the authors / Nature Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41591-026-04206-y · PubMed 41714746.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Nature Medicine for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Nature Medicine study find?

These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.

What type of study is this?

It is a cohort / observational clinical study, published in Nature Medicine in 2026. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41591-026-04206-y. PubMed ID: 41714746. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Petersen KK, Milà-Alomà M, Li Y et al.. Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.. Nature Medicine (2026). DOI: 10.1038/s41591-026-04206-y.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/predicting-onset-of-symptomatic-alzheimer-s-disease-with-plasma-p-tau217-04206y/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides